Medication info
Vildagliptin Metformin Tablets 50/1000 mg (Vildagliptin, Metformin)

Vildagliptin Metformin Tablets 50/1000 mg (Vildagliptin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Vildagliptin Hydrochloride›56mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Hanmi Pharmaceutical Co., Ltd.
Appearance
Dark yellow oval film-coated tablets
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202105310 · Approved 2021.07.13 · Insurance code 643508440

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For the treatment of patients with type 2 diabetes mellitus, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding 100mg of vildagliptin and 2000mg of metformin. Doses of vildagliptin of 100mg or more per day are not recommended. This medicine is generally administered with food or immediately after a meal to reduce gastrointestinal adverse reactions caused by metformin. 1. Patients who have not previously received antidiabetic drug therapy and whose blood glucose cannot be adequately controlled with monotherapy: The initial dose is 1 tablet of this medicine 50/500mg once daily. The dose may be gradually increased to 1 tablet of 50/1000mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this medicine should provide vildagliptin 100mg per day and the patient's existing dose of metformin. The initial dose of this medicine should be determined according to the patient's current treatment regimen. Take 1 tablet of this medicine 50mg/850mg or 50mg/1000mg twice daily, in the morning and evening. 3. Patients switching from combination therapy with vildagliptin and metformin: Patients switching from combination therapy with vildagliptin and metformin to this medicine may start at their existing doses of vildagliptin and metformin. 4. Use in combination with a sulfonylurea or insulin: Administer vildagliptin 50mg twice daily (total daily dose of 100mg) and metformin at a dose similar to the patient's existing dose. - When this medicine is used in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia. No studies have been conducted to evaluate the safety and efficacy of switching from another oral blood glucose-lowering agent to this medicine. Any change in the treatment regimen for type 2 diabetes mellitus may cause changes in blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. If you miss a dose of this medicine, take it with your next meal unless it is time to take the next dose. Do not take a double dose at one time to make up for a missed dose. Patients with hepatic impairment This medicine is not recommended for patients with clinical or laboratory evidence of hepatic impairment, including patients whose ALT or AST levels exceed 2.5 times the upper limit of normal before starting treatment with this medicine.

Ingredients

Manufacturer
Hanmi Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication helps control blood sugar levels in patients with type 2 diabetes by acting through the combined effects of vildagliptin and metformin. When used together with dietary and exercise therapies, it effectively manages blood sugar levels. This helps stabilize blood sugar levels and reduces the risk of complications associated with diabetes. It is important for patients to take this medication consistently to protect their health. This medication is used to improve blood sugar control in type 2 diabetes.

How to take

Adult dose

For the treatment of patients with type 2 diabetes mellitus, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding 100mg of vildagliptin and 2000mg of metformin. Doses of vildagliptin of 100mg or more per day are not recommended. This medicine is generally administered with food or immediately after a meal to reduce gastrointestinal adverse reactions caused by metformin. 1. Patients who have not previously received antidiabetic drug therapy and whose blood glucose cannot be adequately controlled with monotherapy: The initial dose is 1 tablet of this medicine 50/500mg once daily. The dose may be gradually increased to 1 tablet of 50/1000mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this medicine should provide vildagliptin 100mg per day and the patient's existing dose of metformin. The initial dose of this medicine should be determined according to the patient's current treatment regimen. Take 1 tablet of this medicine 50mg/850mg or 50mg/1000mg twice daily, in the morning and evening. 3. Patients switching from combination therapy with vildagliptin and metformin: Patients switching from combination therapy with vildagliptin and metformin to this medicine may start at their existing doses of vildagliptin and metformin. 4. Use in combination with a sulfonylurea or insulin: Administer vildagliptin 50mg twice daily (total daily dose of 100mg) and metformin at a dose similar to the patient's existing dose. - When this medicine is used in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia. No studies have been conducted to evaluate the safety and efficacy of switching from another oral blood glucose-lowering agent to this medicine. Any change in the treatment regimen for type 2 diabetes mellitus may cause changes in blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. If you miss a dose of this medicine, take it with your next meal unless it is time to take the next dose. Do not take a double dose at one time to make up for a missed dose. Patients with hepatic impairment This medicine is not recommended for patients with clinical or laboratory evidence of hepatic impairment, including patients whose ALT or AST levels exceed 2.5 times the upper limit of normal before starting treatment with this medicine.

Precautions

This medication may cause severe lactic acidosis or hypoglycemia, so caution is needed. It should not be administered to patients with moderately severe renal impairment or heart failure, and kidney function should be routinely monitored. For examinations using radiocontrast iodine agents, this medication should be discontinued at least 48 hours prior to the examination, and should only be resumed after confirming normal kidney function. It should not be used in patients with hypersensitivity to this medication or in patients with type 1 diabetes or diabetic ketoacidosis. Patients with severe infections or severe traumatic systemic disorders should temporarily discontinue this medication, and if undergoing surgery, it should also be stopped 48 hours prior to the surgery. Patients with liver dysfunction or those who excessively consume alcohol should refrain from using this medication. Women who are pregnant or breastfeeding should not use this medication. Irregular meals, vigorous exercise, and interactions with other medications may increase the risk of hypoglycemia or lactic acidosis, so caution is necessary. Routine testing of liver and kidney functions is required during treatment with this medication, and any symptoms of liver dysfunction should be reported to healthcare professionals immediately. If symptoms of acute pancreatitis arise, the medication should be stopped, and medical attention should be sought immediately. Symptoms of lactic acidosis include difficulty breathing, abdominal pain, muscle cramps, lethargy, and hypothermia, and immediate treatment should be sought if these symptoms occur. Due to the risk of hypoglycemia, especially elderly patients or those with poor nutritional status should monitor their blood sugar levels frequently. This medication does not replace insulin therapy and is not suitable for patients with type 1 diabetes. Alcohol consumption increases the risk of lactic acidosis, so alcohol should be avoided during treatment. Dizziness or drowsiness may occur, so caution is needed when driving or operating machinery. In case of overdose, consult with healthcare professionals immediately, and blood dialysis may be necessary. Keep this medication out of reach of children and avoid transferring it to other containers. Regular monitoring of blood sugar and hematological tests is advised during treatment with this medication, and checking for vitamin B12 deficiency is recommended.

Side effects

  • Lactic acidosis
  • hypoglycemia
  • hepatitis
  • liver dysfunction
  • elevated transaminase levels
  • angioedema
  • tremors
  • headache
  • dizziness
  • fatigue
Show 43 more
  • nausea
  • gastroesophageal reflux
  • diarrhea
  • bloating
  • chills
  • decrease in blood sugar
  • asthenia
  • sweating
  • constipation
  • joint pain
  • upper respiratory infection
  • nasopharyngitis
  • peripheral edema
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • taste disorder
  • erythema
  • pruritus
  • urticaria
  • pancreatitis
  • urticaria
  • blisters
  • exfoliative skin lesions
  • cutaneous vascular inflammation
  • cholecystitis
  • dyspepsia
  • abdominal discomfort
  • gastrointestinal disorders
  • elevated serum amylase
  • increased lipase
  • vesicular dermatitis
  • myalgia
  • paresthesia
  • fever
  • edema
  • peripheral edema
  • elevated creatine phosphokinase
  • elevated AST
  • elevated C-reactive protein
  • elevated myoglobin levels

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it must be stored in a tightly sealed container. The appropriate storage temperature is room temperature between 1 degree and 30 degrees, and it should be kept away from humid areas.

Appearance and packaging

Appearance

Dark yellow oval film-coated tablets

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.